Increased mediator complex subunit 15 expression is associated with poor prognosis in hepatocellular carcinoma

Mediator complex subunit 15 (MED15) is a coactivator involved in the regulated transcription of RNA polymerase II-dependent genes and serves an oncogenic role in numerous types of cancer. However, the expression and function of MED15 in hepatocellular carcinoma (HCC) remain unknown. In the present s...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2018-04, Vol.15 (4), p.4303-4313
Main Authors: Wang, Kunyuan, Duan, Chenxi, Zou, Xuejing, Song, Yang, Li, Wenwen, Xiao, Lushan, Peng, Jie, Yao, Liheng, Long, Qian, Liu, Li
Format: Article
Language:English
Subjects:
Biotechnology
Care and treatment
Comparative analysis
Confidence intervals
Development and progression
Gene expression
Genetic aspects
Genomes
Health aspects
Hepatocellular carcinoma
Liver cancer
Medical prognosis
Metastasis
Mortality
Multivariate analysis
Oncology
Prognosis
Regression analysis
Transcriptional coactivators
Tumorigenesis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mediator complex subunit 15 (MED15) is a coactivator involved in the regulated transcription of RNA polymerase II-dependent genes and serves an oncogenic role in numerous types of cancer. However, the expression and function of MED15 in hepatocellular carcinoma (HCC) remain unknown. In the present study, the aim was to investigate the expression and clinical significance of MED15 in HCC. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and immunohistochemical analysis revealed that MED15 mRNA and protein levels were significantly upregulated in HCC tissues compared with those in the corresponding adjacent non-tumor liver tissues. Furthermore, analyzing data from The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) and GSE14520 datasets revealed a significant correlation between MED15 expression and the tumor size (P=0.033), Barcelona Clinic Liver Cancer stage (P=0.031), α-fetoprotein levels (P=0.002) and metastasis risk (P=0.001). Furthermore, patients with high MED15 expression levels had a shorter survival time compared with those with low MED15 expression levels (P
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2018.7820